N,N Dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment
Open Access
- 8 February 2017
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep42108
Abstract
N,N-Dimethylacetamide (DMA) is a water-miscible solvent, FDA approved as excipient and therefore widely used as drug-delivery vehicle. As such, DMA should be devoid of any bioactivity. Here we report that DMA is epigenetically active since it binds bromodomains and inhibits osteoclastogenesis and inflammation. Moreover, DMA enhances bone regeneration in vivo. Therefore, our in vivo and in vitro data reveal DMA’s potential as an anti-osteoporotic agent via the inhibition of osteoclast mediated bone resorption and enhanced bone regeneration. Our results highlight the potential therapeutic benefits of DMA and the need for reconsideration of previous reports where DMA was used as an ‘inactive’ drug-delivery vehicle.Keywords
This publication has 40 references indexed in Scilit:
- Targeting bromodomains: epigenetic readers of lysine acetylationNature Reviews Drug Discovery, 2014
- Inflammatory Markers and Risk of Hip Fracture in Older White Women: The Study of Osteoporotic FracturesJournal of Bone and Mineral Research, 2014
- Suppression of inflammation by a synthetic histone mimicNature, 2010
- Selective inhibition of BET bromodomainsNature, 2010
- An emerging role for bromodomain‐containing proteins in chromatin regulation and transcriptional control of adipogenesisFEBS Letters, 2010
- Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelAMolecular and Cellular Biology, 2009
- Selective Small Molecules Blocking HIV-1 Tat and Coactivator PCAF AssociationJournal of the American Chemical Society, 2005
- Inflammatory Markers and the Risk of Coronary Heart Disease in Men and WomenNew England Journal of Medicine, 2004
- Inflammatory Markers and Risk of Developing Type 2 Diabetes in WomenDiabetes, 2004
- Interleukin-6 and risk of cognitive declineNeurology, 2002